A Louisiana-based biopharmaceutical company is betting that its experimental immunotherapeutic vaccine can keep previously untreated prostate cancer in check. The company, OncBioMune Pharnaceuticals, ...
Extended follow-up demonstrated reduced mortality risk with pTVG-HP plus GM-CSF versus GM-CSF alone (median OS 13.4 vs 8.6 years; ~58% risk reduction). Two-year primary metastasis-related endpoints ...
Sowing the Soil for Cure? Results of the ABCSG-12 Trial Open a New Chapter in the Evolving Adjuvant Bisphosphonate Story in Early Breast Cancer Prostatic acid phosphatase (PAP) is a prostate tumor ...
Helen Branswell covered issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Health secretary Robert F. Kennedy Jr. has expressed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results